NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

1923.90 -13.00 (-0.67%)

50.83% Gain from 52W Low

249.1K NSE+BSE Volume

NSE 29 Aug, 2025 3:31 PM (IST)

54,292.6

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

16 Aug 2016

1923.90

-0.67%

Glenmark - 1QFY17 Result Update

Hold: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Reliance Securities

Glenmark Pharmaceuticals' (GNP) Sales, EBITDA & PAT stood at Rs19.4bn, Rs3.8bn & Rs2.2bn, respectively in 1QFY17. Revenue from US business (~37% of sales) rose 18% yoy to US$104mn in 1QFY17 (vs. US$97mn in Q4FY16 & US$89mn in Q1FY16) due to new product approvals. Revenue from India business (~27% of sales) grew by just 10% yoy to Rs5.1bn due to adverse impact of New Pricing Policy and ban on several fixed dose combinations. Revenue from semi-regulated markets (10% of sales) grew 23% yoy due to strong growth in Russia (50% yoy in CC terms). LatAm (~8% of sales) degrew 29% yoy due to negligible contribution from Venezuela and weak performance in Brazil...

Glenmark Pharmaceuti.. has an average target of 1835.00 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

13 Aug 2016

1923.90

-0.67%

Glenmark Pharma: Operational performance in line; PAT beat due to for

Neutral: Glenmark Pharmaceuticals Ltd.

Motilal Oswal

Glenmark Pharma (GNP) reported revenues of INR18.8b (+16% YoY; 2% miss), driven by strong growth in the US, Europe, ROW and API businesses. EBITDA margin came in at 17%, in line with our estimate. Reported PAT of INR2.3b (+24% YoY) was 44% above...

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Glenmark Pharmaceuticals Ltd.

02 Jun 2016

1923.90

-0.67%

Glenmark Pharmaceuticals Ltd.

Buy: Glenmark Pharmaceuticals Ltd.

Ashika Research

off the EBITDA was ~Rs. 460 crore i.e. 20% of revenues. Adjusted for these, margins improved 310bps. Adjusted net profit grew Avg. daily volume (1yr. on NSE)...

Glenmark Pharmaceuticals Ltd. has gained 46.49% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

16 May 2016

1923.90

-0.67%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Revenues grew 28.5% YoY to | 2281.3 crore (I-direct estimate: | 1849.6 crore) mainly on account of robust growth across geographies. The company witnessed 21.6% YoY growth in the US to...

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2059.6

Glenmark Pharmaceuticals Ltd.

16 May 2016

1923.90

-0.67%

Glenmark Q4FY16 Update 16May2016

Buy: Glenmark Pharmaceuticals Ltd.

Target

Phillip Capital

ROW (+36%) and LatAm (+34%) sales. US sales of US$ 97mn were inline with our estimates.CoreoperatingmarginadjustingforforexlossofRs840mnandonetime SitagliptinrelatedlitigationcostofRs650mn)compressedby~260bpsyoyto19.8%...

ICICI Securities Limited decreased Sell price target of Glenmark Pharmaceuticals Ltd. to 1570.0 on 19 Aug, 2025.

Glenmark Pharmaceuticals Ltd.

30 Jan 2016

1923.90

-0.67%

Glenmark 30Jan2016

Buy: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Phillip Capital

However, margin performance was just about in line as improving revenue mix towards bettermargindomestic/USbusinessraisedEBITDAmarginsby80bpsto22.6%.Ledbylower salesandhighertaxincidenceof33%,PAT(adjustedforforexlossofRs270mn)was19%...

Glenmark Pharmaceuticals Ltd. has gained 32.04% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

29 Jan 2016

1923.90

-0.67%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

ICICI Securities Limited

ICICI Securities Limited decreased Sell price target of Glenmark Pharmaceuticals Ltd. to 1570.0 on 19 Aug, 2025.

Glenmark Pharmaceuticals Ltd.

02 Jan 2016

1923.90

-0.67%

Glenmark Pharmaceuticals Ltd: Diversified Portfolio to Sustain Momentum (Jan 02, 2016)

Buy: Glenmark Pharmaceuticals Ltd.

Karvy

US-Big opportunities ahead: USFDA approval for Glenmark generics hasslowed from 18 in FY11 to 6 in FY15 even as 37 plain filings are pending forapproval for Glenmark. The improved approval rate (8 in H1-FY16) should sustain regular growth while incrementally gZetia (with 180 day exclusivity), gZyvox and gVoricanozole should support an 18% CAGR US formulations growth in FY15-18E.

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Is Glenmark Pharmaceuticals Ltd. worth buying?

570 Votes:

Buy 79.3%

Sell 13.68%

Hold 7.02%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf